Pancreatic cancer is a challenging disease to treat, with one of the worse prognoses of any common cancer.  Researchers have been actively investigating various therapeutic strategies. 

Among these potential targets include newly developed KRAS inhibitors and CDK4/6 inhibitors which target hallmark mutations that are common in pancreatic cancer.   

Cell slide from a microscope

Reprogramming of the PDAC tumor microenvironment with KRAS inhibition

Representative images from syngeneic pancreatic cancer tumor model untreated or treated with the mutant G12D-selective KRAS inhibitor MRTX1133. The abundant deposition of collagen is apparent with commensurate reduction in tumor cellularity. Click to view larger image

While these strategies can slow the growth of the tumor, we believe there is a major opportunity in leveraging the tumor microenvironment and immune system to give rise to more potent therapeutic responses.     

The Witkiewicz-Knudsen research team is taking a multi-pronged approach to define critical genetic nodes in pancreatic cancer to directly target the tumor, while understanding the tumor microenvironment and means to unleash anti-tumor immune responses. 

Journal of Pancreatic Cancer Cover

See the science

Contact the Witkiewicz-Knudsen Lab

Department of Molecular and Cellular Biology
Roswell Park Comprehensive Cancer Center 
Elm and Carlton Streets 
Buffalo, NY 14263 

Email Dr. WitkiewiczEmail Dr. Knudsen